Management of fatty liver disease with the metabolic syndrome

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 5, 2014, Pages 487-500

  Machado, Mariana Verdelho ^a   Cortez Pinto, Helena ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Cardiovascular risk; Insulin resistance; Management; Metabolic syndrome; Non alcoholic fatty liver disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA TOCOPHEROL; AMINOTRANSFERASE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; FRUCTOSE; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOSARTAN; METFORMIN; PIOGLITAZONE; PLACEBO; POLYUNSATURATED FATTY ACID; PROBIOTIC AGENT; PROTEIN; SATURATED FATTY ACID; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; BIOLOGICAL MARKER;

ALCOHOL CONSUMPTION; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ASIAN; ATHEROSCLEROSIS; BARIATRIC SURGERY; CALORIC INTAKE; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COFFEE; COGNITIVE THERAPY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXERCISE; FAT INTAKE; FATTY LIVER; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPOLYSIS; LIVER CELL; LIVER FIBROSIS; METABOLIC DISORDER; MITOCHONDRIAL RESPIRATION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PATHOGENESIS; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; REVIEW; RISK REDUCTION; SEX DIFFERENCE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84902284667     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.903798     Document Type: Review

References (154)

1. Baumeister SE, Volzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs in a general population: A 5Yyear observation. Gastroenterology 2008;134(1):85Y94
2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonYalcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142(7):1592Y609
3. Ratziu V, Bellentani S, CortezYPinto H, et al. A position statement on NAFLD/ NASH based on the EASL 2009 special conference. J Hepatol 2010;53(2): 372Y84
4. Gao X, Fan JG; Study Group of Liver and Metabolism, Chinese Society of Endocrinology. Diagnosis and management of nonYalcoholic fatty liver disease and related metabolic disorders: Consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes 2013;5(4):406Y15
5. Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middleYaged and elderly U.S. adults. N Engl J Med 1997;337(24):1705Y14
6. Musso G, Gambino R, Cassader M, Pagano G. MetaYanalysis: Natural history of nonYalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of nonYinvasive tests for liver disease severity. Ann Med 2011; 43(8):617Y49
7. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141(4):1249Y53
8. Tarantino G, Finelli C. What about nonYalcoholic fatty liver disease as a new criterion to define metabolic syndrome?. World J Gastroenterol 2013;19(22):3375Y84
9. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and metaYanalysis. J Am Coll Cardiol 2010;56(14):1113Y32
10. Ducluzeau PH, Boursier J, Bertrais S, et al. MRI measurement of liver fat content predicts the metabolic syndrome. Diabetes Metab 2013;39(4):314Y21
11. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: Lesson from the Dionysos study. J Hepatol 2001;35(4):531Y7
12. Wong VW, Wong GL, Choi PC, et al. Disease progression of nonYalcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. Gut 2010;59(7): 969Y74
13. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10(6):330Y44
14. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49(5):749Y58
15. Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008;19(8): 1564Y70
16. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: A communityYbased cohort study. Am J Gastroenterol 2010;105(7):1567Y73
17. Margariti E, Deutsch M, Manolakopoulos S, Papatheodoridis GV. Nonalcoholic fatty liver disease may develop in individuals with normal body mass index. J Gastroenterol 2012;25(1):45Y51
18. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988Y1994. Arch Intern Med 2003;163(4): 427Y36
19. Messier V, Karelis AD, Robillard ME, et al. Metabolically healthy but obese individuals: Relationship with hepatic enzymes. Metabolism 2010;59(1):20Y4
20. Tarantino G, Caputi A. JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. World J Gastroenterol 2011;17(33): 3785Y94
21. Wang Y, Li YY, Nie YQ, et al. Association between metabolic syndrome and the development of nonYalcoholic fatty liver disease. Exp Ther Med 2013;6(1):77Y84
22. Porepa L, Ray JG, SanchezYRomeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 2010;2(11):26Y531
23. Fraser A, Harris R, Sattar N, et al. Alanine aminotransferase, gammaYglutamyltransferase, and incident diabetes: The British Women's Heart and Health Study and metaYanalysis. Diabetes Care 2009;32(4):741Y50
24. Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010;25(2):352Y6
25. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab 2011;96(4):1093Y7
26. Bae JC, Rhee EJ, Lee WY, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: A 4Yyear retrospective longitudinal study. Diabetes Care 2011; 34(3):727Y9
27. Cicero AF, D'Addato S, Reggi A, On Behalf Of The Brisighella Heart Study C. Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study. Metab Syndr Relat Disord 2013; 11(6):412Y16
28. Ekstedt M, Franzen LE, Mathiesen UL, et al. LongYterm followYup of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44(4):865Y73
29. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012;10(6):646Y50
30. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007;30(8):2119Y21
31. Assy N, Djibre A, Farah R, et al. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010;254(2):393Y400
32. Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with nonYalcoholic fatty liver disease. Gut 2011;60(12):1721Y7
33. Colak Y, Senates E, Yesil A, et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013;43(1):100Y7
34. Lee YJ, Shim JY, Moon BS, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012;57(1):196Y203
35. Sookoian S, Pirola CJ. NonYalcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. J Hepatol 2008;49(4):600Y7
36. Hallsworth K, Hollingsworth KG, Thoma C, et al. Cardiac structure and function are altered in adults with nonYalcoholic fatty liver disease. J Hepatol 2013;58(4):757Y62
37. Rijzewijk LJ, Jonker JT, van Der Meer RW, et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010;56(3): 225Y33
38. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratinY18 as a biomarker for NASH and fibrosis in patients with nonYalcoholic fatty liver disease. J Hepatol 2014;60(1):167Y74
39. Machado MV, CortezYPinto H. NonYinvasive diagnosis of nonYalcoholic fatty liver disease. A critical appraisal. J Hepatol 2013;58(5):1007Y19
40. Bozzetto L, Prinster A, Annuzzi G, et al. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 2012;35(7):1429Y35
41. ZelberYSagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population During a sevenYyear prospective followYup. J Hepatol 2012;56(5):1145Y51
42. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51(1): 121Y9
43. Harrison SA, Fecht W, Brunt EM, NeuschwanderYTetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009;49(1):80Y6
44. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of nonYalcoholic fatty liver disease in adults: A systematic review. J Hepatol 2012;56(1): 255Y66
45. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12(2):224Y9
46. Kwon OW, Jun DW, Lee SM, et al. Carbohydrate but not fat is associated with elevated aminotransferases. Aliment Pharmacol Ther 2012. [Epub ahead of print]
47. Santos FL, Esteves SS, da Costa Pereira A, et al. Systematic review and metaYanalysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev 2012;13(11):1048Y66
48. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weightYloss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360(9): 859Y73
49. Kirk E, Reeds DN, Finck BN, et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009;136(5):1552Y60
50. Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011;53(5): 1504Y14
51. Westerbacka J, Lammi K, Hakkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005;90(5):2804Y9
52. Browning JD, Baker JA, Rogers T, et al. ShortYterm weight loss and hepatic triglyceride reduction: Evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 2011;93(5):1048Y52
53. Johnston RD, Stephenson MC, Crossland H, et al. No difference between highYfructose and highYglucose diets on liver triacylglycerol or biochemistry in healthy overweight men. Gastroenterology 2013; 5(5):16Y1025; e1012
54. Abid A, Taha O, Nseir W, et al. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 2009;51(5):918Y24
55. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010;51(6):1961Y71
56. Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of nonYobese patients with nonYalcoholic fatty liver disease: The significance of dietary cholesterol. Scand J Gastroenterol 2009; 44(4):471Y7
57. Caballero F, Fernandez A, De Lacy AM, et al. Enhanced free cholesterol, SREBPY2 and StAR expression in human NASH. J Hepatol 2009;50(4):789Y96
58. Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between Dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 2009;50(1):175Y84
59. Musso G, Gambino R, Michieli F, Cassader M. Dietary Habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909Y15
60. Machado MV, Ravasco P, Jesus L, et al. Blood oxidative stress markers in nonYalcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol 2008;43(1):95Y102
61. Cao J, Dai DL, Yao L, et al. Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway. Mol Cell Biochem 2011;364(1Y2):115Y29
62. Ricchi M, Odoardi MR, Carulli L, et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009;24(5):830Y40
63. CortezYPinto H, Jesus L, Barros H, et al. How different is the dietary pattern in nonYalcoholic steatohepatitis patients?. Clin Nutr 2006(25):816Y23
64. Toshimitsu K, Matsuura B, Ohkubo I, et al. Dietary habits and nutrient intake in nonYalcoholic steatohepatitis. Nutrition 2007;23(1):46Y52
65. Sawada N, Inoue M, Iwasaki M, et al. Consumption of nY3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology 2012;142(7):1468Y75
66. Parker HM, Johnson NA, Burdon CA, et al. OmegaY3 supplementation and nonYalcoholic fatty liver disease: A systematic review and metaYanalysis. J Hepatol 2012; 56(4):944Y51
67. Risk and Prevention Study Collaborative Group. Roncaglioni MC, Tombesi M, Avanzini F, et al. nY3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368(19):1800Y8
68. Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean Diet improves hepatic steatosis and insulin sensitivity in individuals with nonYalcoholic fatty liver disease. J Hepatol 2013;59(1):138Y43
69. Sun Q, Ma J, Campos H, et al. A prospective study of trans fatty acids in erythrocytes and risk of coronary heart disease. Circulation 2007;115(14):1858Y65
70. Obara N, Fukushima K, Ueno Y, et al. Possible involvement and the mechanisms of excess transYfatty acid consumption in severe NAFLD in mice. J Hepatol 2010;53(2): 326Y34
71. ZelberYSagi S, NitzanYKaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for nonYalcoholic fatty liver disease (NAFLD): A population based study. J Hepatol 2007;47(5):711Y17
72. Ricci G, Canducci E, Pasini V, et al. Nutrient intake in Italian obese patients: Relationships with insulin resistance and markers of nonYalcoholic fatty liver disease. Nutrition 2011;27(6):672Y6
73. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008;47(6):1947Y54
74. Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with nonYalcoholic fatty liver disease (NAFLD). J Hepatol 2012;57(2): 384Y91
75. Moriya A, Iwasaki Y, Ohguchi S, et al. Alcohol consumption appears to protect against nonYalcoholic fatty liver disease. Aliment Pharmacol Ther 2011;33(3): 378Y88
76. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132(2):112Y17
77. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005;3(12):1260Y8
78. Loomba R, Yang HI, Su J, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: A prospective cohort study. Am J Epidemiol 2013;177(4):333Y42
79. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51(6):1972Y8
80. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on Diabetes mellitus: A systematic review. Ann Intern Med 2004;140(3):211Y19
81. Shai I, Wainstein J, HarmanYBoehm I, et al. Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: A multicenter, randomized, clinical intervention trial. Diabetes Care 2007; 30(12):3011Y16
82. Davies MJ, Baer DJ, Judd JT, et al. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: A randomized controlled trial. JAMA 2002;287(19):2559Y62
83. Athyros VG, Liberopoulos EN, Mikhailidis DP, et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiology 2007; 58(6):689Y97
84. King DE, Mainous AG III, Geesey ME. Adopting moderate alcohol consumption in middle age: Subsequent cardiovascular events. Am J Med 2008;121(3):201Y6
85. Di Castelnuovo A, Costanzo S, Bagnardi V, et al. Alcohol dosing and total mortality in men and women: An updated metaYanalysis of 34 prospective studies. Arch Intern Med 2006;166(22):2437Y45
86. FlensborgYMadsen T, Knop J, Mortensen EL, et al. Amount of alcohol consumption and risk of developing alcoholism in men and women. Alcohol Alcohol 2007;42(5):442Y7
87. Yesil A, Yilmaz Y. Review article: Coffee consumption, the metabolic syndrome and nonYalcoholic fatty liver disease. Aliment Pharmacol Ther 2013;38(9):1038Y44
88. Hino A, Adachi H, Enomoto M, et al. Habitual coffee but not green tea consumption is inversely associated with metabolic syndrome: An epidemiological study in a general Japanese population. Diabetes Res Clin Pract 2007;76(3):383Y9
89. Takami H, Nakamoto M, Uemura H, et al. Inverse correlation between coffee consumption and prevalence of metabolic syndrome: Baseline survey of the Japan MultiYInstitutional Collaborative Cohort (JYMICC) Study in Tokushima, Japan. J Epidemiol 2013;23(1):12Y20
90. Driessen MT, Koppes LL, Veldhuis L, et al. Coffee consumption is not related to the metabolic syndrome at the age of 36 years: The Amsterdam Growth and Health Longitudinal Study. Eur J Clin Nutr 2009; 63(4):536Y42
91. Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with nonYalcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35(1):76Y82
92. Molloy JW, Calcagno CJ, Williams CD, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012;55(2): 429Y36
93. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20(4):537Y44
94. Sullivan S, Kirk EP, Mittendorfer B, et al. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012;55(6):1738Y45
95. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in nonYalcoholic fatty liver disease independent of weight loss. Gut 2011;60(9):1278Y83
96. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50(4):1105Y12
97. Tamura Y, Tanaka Y, Sato F, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005;90(6):3191Y6
98. Gauthier MS, Couturier K, Latour JG, Lavoie JM. Concurrent exercise prevents highYfatYdietYinduced macrovesicular hepatic steatosis. Eur J Appl Physiol 2003;94(6): 2127Y34
99. Slentz CA, Bateman LA, Willis LH, et al. Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. Am J Physiol 2011;301(5):E1033Y9
100. Bacchi E, Negri C, Targher G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial). Hepatology 2013;58(4):1287Y95
101. Fenkci S, Sarsan A, Rota S, Ardic F. Effects of resistance or aerobic exercises on metabolic parameters in obese women who are not on a diet. Adv Ther 2006;23(3): 404Y13
102. O'Donovan G, Kearney EM, Nevill AM, et al. The effects of 24 weeks of moderateor highYintensity exercise on insulin resistance. Eur J Appl Physiol 2005;95(5Y6): 522Y8
103. Scaglioni F, Marino M, Ciccia S, et al. ShortYterm multidisciplinary nonYpharmacological intervention is effective in reducing liver fat content assessed nonYinvasively in patients with nonalcoholic fatty liver disease (NAFLD). Clin Res Hepatol Gastroenterol 2013;37(4):353Y8
104. Younossi ZM, Reyes MJ, Mishra A, et al. Systematic review with metaYanalysis: NonYalcoholic steatohepatitis Y a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014; 39(1):3Y14
105. Vongsuvanh R, George J, Qiao L, van Der Poorten D. Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett 2013;330(1):1Y10
106. Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, nonYalcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20(6): 623Y8
107. ZelberYSagi S, Kessler A, Brazowsky E, et al. A doubleYblind randomized placebocontrolled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4(5):639Y44
108. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus nonYsurgical treatment for obesity: A systematic review and metaYanalysis of randomised controlled trials. BMJ 2013;347:f5934
109. Ikramuddin S, Korner J, Lee WJ, et al. RouxYenYY gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: The Diabetes Surgery Study randomized clinical trial. JAMA 2013; 309(21):2240Y9
110. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and metaYanalysis. Clin Gastroenterol Hepatol 2008;6(12): 1396Y402
111. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the longYterm effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009;137(2):532Y40
112. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362(18):1675Y85
113. Hoofnagle JH, Van Natta ML, Kleiner DE, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with nonYalcoholic steatohepatitis. Aliment Pharmacol Ther 2013;38(2):134Y43
114. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011; 305(16):1659Y68
115. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in nonYalcoholic fatty liver disease (NAFLD): A systematic review and metaYanalysis of randomised trials. Diabetologia 2012;55(4):885Y904
116. Miller ER III, PastorYBarriuso R, Dalal D, et al. MetaYanalysis: HighYdosage vitamin E supplementation may increase allYcause mortality. Ann Intern Med 2005;142(1): 37Y46
117. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306(14):1549Y56
118. Schurks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: MetaYanalysis of randomised controlled trials. BMJ 2010;341:c5702
119. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of nonYalcoholic fatty liver disease and nonYalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34(3): 274Y85
120. Belfort R, Harrison SA, Brown K, et al. A placeboYcontrolled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355(22):2297Y307
121. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placeboYcontrolled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135(4):1176Y84
122. Mahady SE, Webster AC, Walker S, et al. The role of thiazolidinediones in nonYalcoholic steatohepatitis Y a systematic review and meta analysis. J Hepatol 2011; 55(6):1383Y90
123. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46(2):424Y9
124. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011;34(4):916Y22
125. Kenny PR, Brady DE, Torres DM, et al. Exenatide in the treatment of diabetic patients with nonYalcoholic steatohepatitis: A case series. Am J Gastroenterol 2010; 105(12):2707Y9
126. Cuthbertson DJ, Irwin A, Gardner CJ, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagonYlike peptideY1 (GLPY1) receptor agonists. PLoS One 2012; 7(12):e50117
127. Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008;57(12): 1711Y18
128. Hyogo H, Yamagishi S, Maeda S, et al. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factorYalphaYlowering property. Dig Liver Dis 2012;44(6):492Y6
129. GomezYDominguez E, Gisbert JP, MorenoYMonteagudo JA, et al. A pilot study of atorvastatin treatment in Dyslipemid, nonYalcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23(11):1643Y7
130. Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placeboYcontrolled trial. J Clin Gastroenterol 2009;43(10):990Y4
131. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Are statins 'IDEAL' for nonYalcoholic fatty liver disease?. Curr Med Res Opin 2014;30(2):229Y31
132. Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and metaYanalysis. Gastroenterology 2013; 144(2):323Y32
133. Pradelli D, Soranna D, Scotti L, et al. Statins and primary liver cancer: A metaYanalysis of observational studies. Eur J Cancer Prev 2013;22(3):229Y34
134. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: A metaYanalysis. JAMA 2006;295(1):74Y80
135. Cholesterol Treatment Trialists Collaboration. Emberson JR, Kearney PM, et al. Lack of effect of lowering LDL cholesterol on cancer: MetaYanalysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012;7(1):e29849
136. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on nonYalcoholic fatty liver disease in metabolic syndrome: A randomised study. Curr Med Res Opin 2006;22(5):873Y83
137. FernandezYMiranda C, PerezYCarreras M, Colina F, et al. A pilot trial of fenofibrate for the treatment of nonYalcoholic fatty liver disease. Dig Liver Dis 2008;40(3):200Y5
138. Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of nonYalcoholic steatohepatitis: A doubleYblind randomized controlled study. J Hepatol 2003;38(4): 414Y18
139. Ishitobi T, Hyogo H, Tokumo H, et al. Efficacy of probucol for the treatment of nonYalcoholic steatohepatitis with dyslipidemia: An openYlabel pilot study. Hepatol Res 2013. [Epub ahead of print]
140. Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment of nonYalcoholic steatohepatitis: An openYlabel, pilot study. Hepatol Res 2010;40(6):566Y73
141. Park H, Shima T, Yamaguchi K, et al. Efficacy of longYterm ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011;46(1):101Y7
142. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40(5):1222Y5
143. Hirata T, Tomita K, Kawai T, et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty liver protection trial by telmisartan or losartan study (FANTASY). Int J Endocrinol 2013;2013:587140
144. Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of highYdose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54(5): 1011Y19
145. Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009; 29(8):1184Y8
146. Gabbi C, Bertolotti M, Anzivino C, et al. Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of nonYalcoholic fatty liver disease. Dig Liver Dis 2012;44(12):1018Y26
147. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145(3): 574Y82; e571
148. Van Wagner LB, Koppe SW, Brunt EM, et al. Pentoxifylline for the treatment of nonYalcoholic steatohepatitis: A randomized controlled trial. Ann Hepatol 2011;10(3): 277Y86
149. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placeboYcontrolled trial. Hepatology 2011; 54(5):1610Y19
150. Loguercio C, De Simone T, Federico A, et al. GutYliver axis: A new point of attack to treat chronic liver damage?. Am J Gastroenterol 2002;97(8):2144Y6
151. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39(6):540Y3
152. Aller R, De Luis DA, Izaola O, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011;15(9):1090Y5
153. Malaguarnera M, Vacante M, Antic T, et al. Bifidobacterium longum with fructoYoligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57(2):545Y53
154. Wong VW, Won GL, Chim AM, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proofYofYconcept study. Ann Hepatol 2013;12(2):256Y62.